Priut Pharmaceuticals' application for a class 4 generic listing of thioponic acid tebutalin was accepted.

On October 22nd, CDE official website data showed that four generic listing applications for sulphuric acid tebutalin atomization inhalation solution were accepted.
the end of China's public medical institutions Tebutalin inhaler is more than 1 billion varieties, led by AstraZeneta.
April 2020, the same Sichuan pharmaceutical company, the United States Dakang Huakang Pharmaceuticals sulfate tebutalin atomized inhalation solution 6 imitation market application was approved, becoming AstraZenecon's strongest competitor.
Figure 1: Four Trump Rite Pharmaceuticals Sulphate Tebutalin Atomized Inhalation Solution Registration Source: CDE Official Website Figure 2: Top20 Of The End Chemical Inhalant Variety of China's Public Medical Institutions Source: Minnet China's Public Medical Institutions Terminal Competition According to the data of the pattern, there are 8 out of 1 billion kinds of end-chemical inhalants in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions), and Tebutalin ranks in TOP6.
inhaler can be used for bronchial spasms caused by bronchial asthma, chronic bronchitis, obstructive emphysema, or other lung disorders.
Table 1: Currently under review for the listing of Tebutalin inhalants Source: Minet MED2.0 China Drug Review Database is currently approved by the domestic pharmaceutical companies have Haizheng Pharmaceuticals sulphuric acid Tebutalin inhalation powder spray, Sichuan Meida Kang Huakang Pharmaceuticals sulfate tebtalin atomized inhalation solution for 6 types of imitation, the variety has no enterprise evaluation.
Health Yuan, Shijiazhuang four drugs, Hebei Renhe Yikang Pharmaceuticals, Suzhou Hongsen Pharmaceuticals four types of imitation listing applications are currently in the review and approval, pending the approval of domestic inhalers to enter the market, is expected to seize AstraZeneta's market share.
source: CDE official website, Mi Net database original title: Sichuan pharmaceutical companies to make further efforts, into the more than 1 billion inhalers! The AZ exclusive market is over.